Spinal muscular atrophy (SMA) is the most common genetic motoneuron degenerative disorder, but the mechanism(s) of motoneuron death is unclear. Previously, a direct interaction between tumor-suppressive TP53 protein and the SMA determinant gene product, survival motor neuron protein, was identified and therefore it has been suggested that a mechanism of TP53-dependent apoptosis plays an important role in motoneuron degeneration in SMA. We used our SMA model mice, generated by a combination of knockout and transgenic techniques, to decipher the role of TP53 protein in the motoneuron degeneration in SMA. We detected a significant increase of Trp53 expression in the spinal cord of SMA-like mice compared to their normal littermates. After crossing SMA-like mice with Trp53 knockout mice, the progeny Trp53-deficient SMA-like mice did not show milder disease severity or longer lifespan compared to SMA littermates with wild-type Trp53 genes. Our studies provide in vivo evidence indicating that Trp53-dependent apoptosis does not play a crucial role in motoneuron degeneration in SMA-like mice.
Introduction
Spinal muscular atrophy (SMA), an autosomal recessive motoneuron degenerative disorder, is caused by degeneration of the spinal motoneurons leading to muscular paralysis and atrophy. 1 SMA patients are clinically categorized, on the basis of age of disease onset and clinical course, into three types: SMA 1 (the most severe, Werdnig -Hoffmann disease, MIM253300), SMA 2 (the intermediate, MIM253550), and SMA 3 (the mildest, Kugelberg -Welander disease, MIM253400). 2 Mutations of the SMA determinant gene, survival motor neuron (SMN1) gene, are found in about 96% of human SMA patients. 3 Although the relationship between SMA and the SMN1 gene product has been known for years, the neurodegeneration pathways responsible for SMA motoneuron death remain unclear. 1 Previously, we created a SMA mouse model by a combination of knockout and transgenic techniques. 4 The offspring SMA-like mice with homologous mouse Smn gene knockouts and hemizygous human SMN2 transgenes (genotype: Smn À/À SMN2 þ /À ), genotypically and phenotypically mimic SMA patients, and they can be categorized into three clinical types in the same way as human patients according to the phenotypes and survival times. 4 Therefore, these SMA-like mice are suitable for use in studying the mechanism of SMA motoneuron degeneration. Tumor-suppressive TP53 protein, which can induce cell cycle arrest and apoptosis, performs a critical role in the regulation of neuronal differentiation and apoptosis. 5, 6 TP53 can induce neuronal death through a Bax-dependent pathway by directly transactivating proapoptotic Bax expression. 7, 8 Recently, TP53 was reported to directly interact with SMN protein, 9 and therefore TP53-dependent apoptotic pathways were suggested to play a crucial role in the motoneuron loss in SMA disease. 9, 10 To test this hypothesis, in the present study we used our SMA model mice to cross the Trp53 knockout mice. 11 The offspring Trp53-deficent SMA mice did not show milder disease severity or longer lifespan than their SMA littermates with wild-type Trp53 genes, but some of them showed different phenotypes and neurodegeneration in the brain stems. This constitutes in vivo evidence against the hypothesis that TP53-dependent apoptotic pathways play a crucial role in motoneuron loss in SMA disease. We analyzed the genotypes of Smn knockout, SMN2 transgenic, and Trp53 knockout mice by polymerase chain reaction (PCR) analysis. Mouse tail genomic DNAs were prepared as previously described. 4 The three specific PCR primers (S1, S2, and H1) were used for detection of the wild-type and knockout Smn alleles, and the primer pair (3F and 3B) were used to identify the human SMN2 transgenes. 4 The three specific primers (primer 4b, primer 6, and primer in the polII promoter region) were used to identify the wild-type and knockout Trp53 alleles. 11 For statistical analyses of life spans of mice, differences were compared between two groups by the Student's t-test. The results were considered to be significant when Po0.05.
Materials and methods

Mice
Western blotting, histopathological and immunostaining analyses
We isolated spinal cords from three different clinical types of SMA-like mice and their normal littermates that had been freshly killed. Total proteins were extracted from the spinal cords using extraction buffer containing 0.4% Nonidet P-40, 0.1% sodium dodecylsulfate (SDS), and proteinase inhibitors (Completet proteinase inhibitor Cocktail, Roche Biomedical). Equal amounts of extracted proteins were loaded and proteins were separated by 12% 
Results and discussion
In order to investigate the relationship between Trp53 protein and SMA motoneuron death, we analyzed the expression levels of Trp53 protein within spinal cords of type 1 SMA-like mice and their normal littermates by Western blotting. Dramatically lower SMN levels (about one-tenth) were detected in the spinal cord extracts from type 1 SMA-like mice in comparison with the spinal cord extracts of their normal age-matched littermates, and levels of b-actin were detected as an internal control (Figure 1a ). We found a significant increase in Trp53 expression (2.7870.43 fold) in type 1 SMA-like mice in comparison with their normal littermates (Figure 1a) . Furthermore, a significant increase in Trp53 expression (1.9670.36 fold) was also found in type 2 SMA-like mice but not in type 3 SMA-like mice (1.1170.41 fold) in comparison with their normal littermates (Figure 1b) . Since the more severe SMA-like mice showed the more significant increase in Trp53 expression in their spinal cords, the increase in Trp53 expressions correlated with the disease severities of SMA in SMA-like mice.
To determine the in vivo role of Trp53 protein in SMA motoneuron degeneration, we crossed knockout-transgenic mice (genotype: Figure 2 ). The probabilities of survival for mice were higher before postnatal day 10 and lower after postnatal day 11 in the Trp53 þ / þ SMA than in the Trp53 À/À SMA mice groups. From these results, we can not conclude that Trp53 deficiency prolongs the lifespan of SMA-like mice. Type 2 Trp53 À/À SMA mice that showed severe atrophy of the tail and lower limbs, as well as bleeding from the lower abdomen were obtained (Figure 3a) . However, these phenotypes were not found in type 2 Trp53 þ / þ SMA mice.
Furthermore, type 3 Trp53 À/À SMA mice showed neuronal degeneration in their brain stems that were not detected in their type 3 Trp53 þ / þ SMA littermates (Figures 3b -e) .
These results suggest the possibility that Trp53 deficiency in SMA-like mice changed the pathophysiology and symptoms of SMA disease. The mechanism of this change needs to be further analyzed. We previously found in vivo evidence that showed that Bax-dependent apoptosis played a crucial role in motoneuron degeneration in SMA (Tsai et al, unpublished data). Here, we detected an increase in Trp53 expression in spinal cords of type 1 and type 2 SMA-like mice compared to normal littermates (Figure 1a and b ). An increase in Trp53 expression was also detected in the spinal motoneurons of amyotrophic lateral sclerosis 1 (ALS1, MIM105400) model mice.
14 Furthermore, TP53
can directly interact with SMN protein; a decrease in SMN protein expression in SMA patients inhibited TP53-SMN complex formation, thus promoting the translocation of TP53 into nucleolus. 9 Therefore, a possible mechanism for motoneuron loss by TP53-dependent apoptosis has been suggested for both ALS and SMA 
